Advanced search
Publication Cover
Future Medicinal Chemistry Volume 6, 2014 - Issue 8
Submit an article Journal homepage
1,155
Views
0
CrossRef citations to date
0
Altmetric
Review

Conformational Restriction: An Effective Tactic in ‘Follow-On’-Based Drug Discovery

Zengjun Fang1 Department of Medicinal Chemistry, Key laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44, West Culture Road, 250012, Jinan, Shandong, P. R. ChinaView further author information
,
Yu’ning Song2 Department of Pharmacology, Key laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44, West Culture Road, 250012, Jinan, Shandong, P. R. ChinaView further author information
,
Peng Zhan1 Department of Medicinal Chemistry, Key laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44, West Culture Road, 250012, Jinan, Shandong, P. R. ChinaCorrespondence[email protected]
View further author information
,
Qingzhu Zhang2 Department of Pharmacology, Key laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44, West Culture Road, 250012, Jinan, Shandong, P. R. ChinaView further author information
&
Xinyong Liu1 Department of Medicinal Chemistry, Key laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44, West Culture Road, 250012, Jinan, Shandong, P. R. ChinaView further author information
Pages 885-901 | Published online: 25 Jun 2014

References

  • Raju TN . The Nobel chronicles. 1988: James Whyte Black, (b 1924), Gertrude Elion (19189–9), and George H Hitchings (19059–8). Lancet355, 1022 (2000).
  • Zhao H , GuoZ. Medicinal chemistry strategies in follow-on drug discovery. Drug Discov. Today14, 5165–5122 (2009).
  • Fischer J, Ganellin CR . Analogue-based Drug Discovery. Wiley VCH, Weinheim, Germany (2006).
  • Fischer J, Ganellin CR . Analogue-Based Drug Discovery II. Wiley VCH, Weinheim, Germany (2010).
  • Fischer J, Ganellin CR, Rotella DP . Analogue-Based Drug Discovery III. Wiley VCH, Weinheim, Germany (2012).
  • Valle G , KazmierskiWM, CrismaM. Constrained phenylalanine analogues. Preferred conformation of the 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic) residue. Int. J. Pept. Protein Res.40 (3–4), 222–232 (1992).
  • Kümmerle AE , VieiraMM, SchmittMet al. Design, synthesis and analgesic properties of novel conformationally-restricted N-acylhydrazones (NAH). Bioorg. Med. Chem. Lett.19 (17), 4963–4966 (2009).
  • Hanessian S , AuzzasL. The practice of ring constraint in peptidomimetics using bicyclic and polycyclic amino acids. Acc. Chem. Res.41 (10), 1241–1251 (2008).
  • Chang CE , ChenW, GilsonMK. Ligand configurational entropy and protein binding. Proc. Natl Acad. Sci. USA104 (5), 1534–1539 (2007).
  • Tiwari RK , ParangK. Conformationally constrained peptides as protein tyrosine kinase inhibitors. Curr. Pharm. Des.18 (20), 2852–2566 (2012).
  • Parkin DM , BrayF, FerlayJ, PisaniP. Global cancer statistics, 2002. CA Cancer J. Clin.55, 74–108 (2005).
  • Doody RS , FerrisSH, SallowaySet al. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology72 (18), 1555–1561 (2009).
  • van Marum RJ . Update on the use of memantine in Alzheimer's disease. Neuropsychiatr. Dis. Treat.5, 237–247 (2009).
  • Farlow MR , CummingsJL. Effective pharmacologic management of Alzheimer's disease. Am. J. Med.120 (5), 388–397 (2007).
  • Bolognesi ML , BartoliniM, CavalliAet al. Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues. J. Med. Chem.47 (24), 5945–5952 (2004).
  • Boy KM , GuernonJM, ShiJet al. Monosubstituted γ-lactam and conformationally constrained 1,3-diaminopropan-2-ol transition-state isostere inhibitors of β-secretase (BACE). Bioorg. Med. Chem. Lett.21 (22), 6916–6924 (2011).
  • Al-Tel TH , SemreenMH, Al-QawasmehRAet al. Design, synthesis, and qualitative structure-activity evaluations of novel β-secretase inhibitors as potential Alzheimer's drug leads. J. Med. Chem.54 (24), 8373–8385 (2011).
  • Stachel SJ , SteeleTG, PetrocchiAet al. Discovery of pyrrolidine-based β-secretase inhibitors: lead advancement through conformational design for maintenance of ligand binding efficiency. Bioorg. Med. Chem. Lett.22 (1), 240–244 (2012).
  • Mandal M , ZhuZ, CummingJNet al. Design and validation of bicyclic iminopyrimidinones as beta amyloid cleaving enzyme-1 (BACE1) inhibitors: conformational constraint to favor a bioactive conformation. J. Med. Chem.55 (21), 9331–9345 (2012).
  • Yonezawa S , YamamotoT, YamakawaHet al. Conformational restriction approach to β-secretase (BACE1) inhibitors: effect of a cyclopropane ring to induce an alternative binding mode. J. Med. Chem.55 (20), 8838–8858 (2012).
  • Yonezawa S , YamakawaH, MutoCet al. Conformational restriction approach to BACE1 inhibitors II: SAR study of the isocytosine derivatives fixed with a cis-cyclopropane ring. Bioorg. Med. Chem. Lett.23 (10), 2912–2915 (2013).
  • Bischoff F , BerthelotD, De CleynMet al. Design and synthesis of a novel series of bicyclic heterocycles as potent γ-secretase modulators. J. Med. Chem.55 (21), 9089–9106 (2012).
  • Maher-Edwards G , Zvartau-HindM, HunterAJet al. Double-blind, controlled Phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease. Curr. Alzheimer Res.7 (5), 374–385 (2010).
  • Ivachtchenko AV , GolovinaES, KadievaMGet al. Antagonists of 5-HT6 receptors. Substituted 3-(phenylsulfonyl)pyrazolo[1,5-a]pyrido[3,4-e]pyrimidines and 3-(phenylsulfonyl)pyrazolo[1,5-a]pyrido[4,3-d]pyrimidines-synthesis and ‘structure–activity’ relationship. Bioorg. Med. Chem. Lett.22 (13), 4273–4280 (2012).
  • Nirogi R , ShindeA, DaulatabadAet al. Design, synthesis, and pharmacological evaluation of piperidin-4-yl amino aryl sulfonamides: novel, potent, selective, orally active, and brain penetrant 5-HT(6) receptor antagonists. J. Med. Chem.55 (21), 9255–9269 (2012).
  • De Clercq E . A 40-year journey in search of selective antiviral chemotherapy. Annu. Rev. Pharmacol. Toxicol.51, 1–24 (2011).
  • Steen A , SchwartzTW, RosenkildeMM. Targeting CXCR4 in HIV cell-entry inhibition. Mini Rev. Med. Chem.9 (14), 1605–1621 (2009).
  • Valks GC , McRobbieG, LewisEAet al. Configurationally restricted bismacrocyclic CXCR4 receptor antagonists. J. Med. Chem.49 (21), 6162–6165 (2006).
  • Fujii N , OishiS, HiramatsuKet al. Molecular-size reduction of a potent CXCR4-chemokine antagonist using orthogonal combination of conformation- and sequence-based libraries. Angew. Chem. Int. Ed. Engl.42 (28), 3251–3253 (2003).
  • Ueda S , OishiS, WangZXet al. Structure–activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone functionalities. J. Med. Chem.50 (2), 192–198 (2007).
  • Mungalpara J , ThieleS, EriksenOet al. Rational design of conformationally constrained cyclopentapeptide antagonists for C-X-C chemokine receptor 4 (CXCR4). J. Med. Chem.55 (22), 10287–10291 (2012).
  • Demmer O , FrankAO, HagnFet al. A conformationally frozen peptoid boosts CXCR4 affinity and anti-HIV activity. Angew. Chem. Int. Ed. Engl.51 (32), 8110–8113 (2012).
  • Chen W , ZhanP, De ClercqE, LiuX. Recent progress in small molecule CCR5 antagonists as potential HIV-1 entry inhibitors. Curr. Pharm. Des.18 (1), 100–112 (2012).
  • Metz M , BourqueE, LabrecqueJet al. Prospective CCR5 small molecule antagonist compound design using a combined mutagenesis/modeling approach. J. Am. Chem. Soc.133 (41), 16477–16485 (2011).
  • Rotstein DM , GabrielSD, ManserNet al. Synthesis, SAR and evaluation of [1,4′]-bipiperidinyl-4-yl-imidazolidin-2-one derivatives as novel CCR5 antagonists. Bioorg. Med. Chem. Lett.20 (11), 3219–3222 (2010).
  • Duan M , KazmierskiWM, TallantMet al. Discovery of a novel series of cyclic urea as potent CCR5 antagonists. Bioorg. Med. Chem. Lett.21 (21), 6381–6385 (2011).
  • Castonguay LA , WengY, AdolfsenWet al. Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: a molecular modeling-guided mutagenesis study of the binding pocket. Biochemistry42 (6), 1544–1550 (2003).
  • Barber CG , BlakemoreDC, ChivaJYet al. 1-amido-1-phenyl-3-piperidinylbutanes--CCR5 antagonists for the treatment of HIV: part 2. Bioorg. Med. Chem. Lett.19 (5), 1499–1503 (2009).
  • Egbertson MS . HIV integrase inhibitors: from diketoacids to heterocyclic templates: a history of HIV integrase medicinal chemistry at Merck West Point and Merck Rome (IRBM). Curr. Top Med. Chem.7 (13), 1251–1272 (2007).
  • Fardis M , JinH, ChenXet al. Conformationally constrained tricyclic HIV integrase inhibitors. In: HIV-1 Integrase: Mechanism and Inhibitor Design (First Edition). NeamatiN (Ed.). John Wiley & Sons Inc., NY, USA, 239–254 (2011).
  • Zhao XZ , MaddaliK, SmithSJet al. 6,7-dihydroxy-1-oxoisoindoline-4-sulfonamide- containing HIV-1 integrase inhibitors. Bioorg. Med. Chem. Lett.22 (24), 7309–7313 (2012).
  • Fisher TE , KimB, StaasDDet al. 8-hydroxy-3,4-dihydropyrrolo[1,2-a]pyrazine-1(2H)-one HIV-1 integrase inhibitors. Bioorg. Med. Chem. Lett.17 (23), 6511–6515 (2007).
  • Thuring JWJ, Bonfanti J-F, Fortin JMC : WO2011045330 A1 (2011). 
  • Li X , VinceR. Conformationally restrained carbazolone-containing alpha, gamma-diketo acids as inhibitors of HIV integrase. Bioorg. Med. Chem.14 (9), 2942–2955 (2006).
  • Artico M , Di SantoR, CostiRet al. Geometrically and conformationally restrained cinnamoyl compounds as inhibitors of HIV-1 integrase: synthesis, biological evaluation, and molecular modeling. J. Med. Chem.41 (21), 3948–3960 (1998).
  • Buolamwini JK , AssefaH. CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site. J. Med. Chem.45 (4), 841–852 (2002).
  • Kawasuji T , JohnsBA, YoshidaHet al. Carbamoyl pyridone HIV-1 integrase inhibitors. 2. Bi- and tricyclic derivatives result in superior antiviral and pharmacokinetic profiles. J. Med. Chem.56 (3), 1124–1135 (2013).
  • Johnson TW , TanisSP, ButlerSLet al. N-hydroxy-dihydronaphthyridinones as potent and orally bioavailable HIV-1 integrase inhibitors. J. Med. Chem.54 (9), 3393–3417 (2011).
  • Pryde DC , WebsterR, ButlerSLet al. Discovery of an HIV integrase inhibitor with an excellent resistance profile. Med. Chem. Commun.4, 709–719 (2013).
  • Biswas D , SampL, GangulyAK. Synthesis of conformationally restricted sulfonamides via radical cyclisation. Tetrahedron Lett.51, 2681–2684 (2010).
  • Ganguly AK , AlluriSS, CarocciaDet al. Design, synthesis, and x-ray crystallographic analysis of a novel class of HIV-1 protease inhibitors. J. Med. Chem.54 (20), 7176–7183 (2011).
  • Mathé C , PérigaudC. Recent approaches in the synthesis of conformationally restricted nucleoside analogues. Eur. J. Org. Chem.2008 (9), 1489–1505 (2008).
  • Díaz-Rodríguez A , SanghviYS, FernándezSet al. Synthesis and anti-HIV activity of conformationally restricted bicyclic hexahydroisobenzofuran nucleoside analogs. Org. Biomol. Chem.7 (7), 1415–1423 (2009).
  • Figueras A , Miralles-LlumàR, FloresRet al. Synthesis, anti-HIV activity studies, and in silico rationalization of cyclobutane-fused nucleosides. Chem. Med. Chem.7 (6), 1044–1056 (2012).
  • Zhan P , ChenX, LiDet al. HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design. Med. Res. Rev.33 (1), E1–E72 (2013).
  • Zhan P , LiuX. Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005–2010). Expert Opin. Ther. Pat.21 (5), 717–796 (2011).
  • Zhan P , LiuX, LiZ, PannecouqueC, De ClercqE. Design strategies of novel NNRTIs to overcome drug resistance. Curr. Med. Chem.16 (29), 3903–3917 (2009).
  • Zhan P , LiuX, LiZ. Recent advances in the discovery and development of novel HIV-1 NNRTI platforms: 20062-008 update. Curr. Med. Chem.16 (22), 2876–2889 (2009).
  • Song YN , FangZ, ZhanP, LiuX. Recent advances in the discovery and development of novel HIV-1 NNRTI platforms (Part II): 2009-2013 update. Curr. Med. Chem.21 (3), 329–355 (2014).
  • Pauwels R , AndriesK, DesmyterJet al. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature343, 470–474 (1990).
  • Schafer JJ , ShortWR. Rilpivirine, a novel non-nucleoside reverse transcriptase inhibitor for the management of HIV-1 infection: a systematic review. Antivir. Ther.17 (8), 1495–1502 (2012).
  • Klibanov OM , KaczorRL. IDX-899, an aryl phosphinate-indole non-nucleoside reverse transcriptase inhibitor for the potential treatment of HIV infection. Curr. Opin. Invest. Drugs11 (2), 237–245 (2010).
  • Moyle G , BoffitoM, StoehrAet al. Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects. Antimicrob. Agents Chemother.54 (8), 3170–3178 (2010).
  • Wu B , NguyenTN, EllisDAet al. US20080287516 A1 (2008).
  • Gomez R , JollySJ, WilliamsTet al. Design and synthesis of conformationally constrained inhibitors of non-nucleoside reverse transcriptase. J. Med. Chem.54 (22), 7920–7933 (2011).
  • Cantrell AS , EngelhardtP, HögbergMet al. Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs. J. Med. Chem.39 (21), 4261–4274 (1996).
  • Zhang H , ObergB, BottigerDet al. MIV-150 in a vaginal microbicide with superior anti-HIV activities. Presented at: The XV International AIDS Conference. Bangkok, Thailand, 12-16 July 2004.
  • Barreca ML , RaoA, De LucaLet al. Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains. Bioorg. Med. Chem. Lett.17, 1956–1960 (2007).
  • Venkatachalam TK , MaoC, UckunFM. Effect of stereo and regiochemistry towards wild and multidrug resistant HIV-1 virus: viral potency of chiral PETT derivatives. Biochem. Pharmacol.67, 1933–1946 (2004).
  • Salaun, J . Cyclopropane derivatives and their diverse biological activities. In: Small Ring Compounds in Organic Synthesis VI.Springer-Verlag, Berlin, Germany, 240 (1999).
  • Högberg M , SahlbergC, EngelhardtPet al. Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues. J. Med. Chem.42, 4150–4160 (1999).
  • Dmitry A , ChristianS, StefanL, ChristerS. WO2004021969 A2 (2004).
  • Ren J , DiproseJ, WarrenJet al. Phenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases. Structural and biochemical analyses. J. Biol. Chem.275 (8), 5633–5639 (2000).
  • Su DS , LimJJ, TinneyEet al. Substituted tetrahydroquinolines as potent allosteric inhibitors of reverse transcriptase and its key mutants. Bioorg. Med. Chem. Lett.19, 5119–5123 (2009).
  • Radi M , MagaG, AlongiMet al. Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants. J. Med. Chem.52, 840–851 (2009).
  • Jiang T , KuhenKL, WolffKet al. Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I. Bioorg. Med. Chem. Lett.16, 2105–2108 (2006).
  • Jiang T , KuhenKL, WolffKet al. Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2. Bioorg. Med. Chem. Lett.16 (8), 2109–2112 (2006).
  • Ellis D , KuhenKL, AnaclerioBet al. Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett.16, 4246–4251 (2006).
  • Hassam M , BassonAE, LiottaDCet al. Novel Cyclopropyl-Indole Derivatives as HIV Non-Nucleoside Reverse Transcriptase Inhibitors. ACS Med. Chem. Lett.3 (6), 470–475 (2012).
  • Mai A , SbardellaG, ArticoMet al. Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase. J. Med. Chem.44 (16), 2544–2554 (2001).
  • Ragno R , MaiA, SbardellaGet al. Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant. J. Med. Chem.47 (4), 928–934 (2004).
  • Rotili D , SamueleA, TarantinoDet al. 2-(alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as Inhibitors of wild-type and mutant HIV-1: enantioselectivity studies. J. Med. Chem.55 (7), 3558–3562 (2012).
  • Alexandre FR , AmadorA, BotSet al. Synthesis and biological evaluation of aryl-phospho-indole as novel HIV-1 non-nucleoside reverse transcriptase inhibitors. J. Med. Chem.54 (1), 392–395 (2011).
  • Gu SX , LiZM, MaXDet al. Chiral resolution, absolute configuration assignment and biological activity of racemic diarylpyrimidine CH(OH)-DAPY as potent nonnucleoside HIV-1 reverse transcriptase inhibitors. Eur. J. Med. Chem.53, 229–234 (2012).
  • Kang IJ , WangLW, LeeCCet al. Design, synthesis, and anti-HCV activity of thiourea compounds. Bioorg. Med. Chem. Lett.19 (7), 1950–1955 (2009).
  • Kang IJ , WangLW, HsuSJet al. Design and efficient synthesis of novel arylthiourea derivatives as potent hepatitis C virus inhibitors. Bioorg. Med. Chem. Lett.19 (21), 6063–6068 (2009).
  • Kang IJ , WangLW, YehTKet al. Synthesis, activity, and pharmacokinetic properties of a series of conformationally-restricted thiourea analogs as novel hepatitis C virus inhibitors. Bioorg. Med. Chem.18 (17), 6414–6421 (2010).
  • McGowan D , VendevilleS, LinTIet al. Finger-loop inhibitors of the HCV NS5b polymerase. Part 1: Discovery and optimization of novel 1,6- and 2,6-macrocyclic indole series. Bioorg. Med. Chem. Lett.22 (13), 4431–4436 (2012).
  • Vendeville S , LinTI, HuLet al. Finger loop inhibitors of the HCV NS5b polymerase. Part II. Optimization of tetracyclic indole-based macrocycle leading to the discovery of TMC647055. Bioorg. Med. Chem. Lett.22 (13), 4437–4443 (2012).
  • Rudd MT , McIntyreCJ, RomanoJJet al. Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkers. Bioorg. Med. Chem. Lett.22 (23), 7207–7213 (2012).
  • Brant MG , WulffJE. A rigid bicyclic platform for the generation of conformationally locked neuraminidase inhibitors. Org. Lett.14 (23), 5876–5879 (2012).
  • Bastida A , HidalgoA, ChiaraJLet al. Exploring the use of conformationally locked aminoglycosides as a new strategy to overcome bacterial resistance. J. Am. Chem. Soc.128 (1), 100–116 (2006).
  • Wang W , WangS, LiuYet al. Novel conformationally restricted triazole derivatives with potent antifungal activity. Eur. J. Med. Chem.45 (12), 6020–6026 (2010).
  • De Wachter R , de GraafC, KeresztesAet al. Synthesis, biological evaluation, and automated docking of constrained analogues of the opioid peptide H-Dmt-D-Ala-Phe-Gly-NH2 using the 4- or 5-methyl substituted 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one scaffold. J. Med. Chem.54 (19), 6538–6547 (2011).
  • Palomo C , AizpuruaJM, BenitoAet al. Development of a new family of conformationally restricted peptides as potent nucleators of beta-turns. Design, synthesis, structure, and biological evaluation of a beta-lactam peptide analogue of melanostatin. J. Am. Chem. Soc.125 (52), 16243–16260 (2003).
  • Iwata T , TanakaK, TaharaTet al. A conformationally fixed analog of the peptide mimic Grb2-SH2 domain: synthesis and evaluation against the A431 cancer cell. Mol. Biosyst.9 (5), 1019–1025 (2013).
  • Meijler MM , MatsushitaM, AltobellLJ3rd, WirschingP, JandaKD. A new strategy for improved nicotine vaccines using conformationally constrained haptens. J. Am. Chem. Soc.125 (24), 7164–7165 (2003).
  • Zhao PL , WangL, ZhuXLet al. Subnanomolar inhibitor of cytochrome bc1 complex designed by optimizing interaction with conformationally flexible residues. J. Am. Chem. Soc.132 (1), 185–194 (2010).
  • PyMOL0.99. www.pymol.org

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.